Current treatment targets for LDL-C, non-HDL-C and apo B can be used as accurately in the non-fasting state as in the fasting state. The measurement of LDL-C, non-HDL-C and apo B in the non-fasting state does not confer to an increased risk of…
ID
Bron
Verkorte titel
Aandoening
hyperlipidemia
hypercholesterolemia
secondary cardiovascular prevention
Fasting
non-fasting
Ondersteuning
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The number of patients that reach the set treatment target of LDL-C <2.5 mmol/l when using non-fasting blood samples while their fasting LDL is>2.5mmol/l.
Achtergrond van het onderzoek
Background: Current guidelines recommend to measure the lipid profile in the fasting state although evidence is growing that a non-fasting lipid profile is sufficient most of the time and more convenient for both physicians and patients. However, comparisons between the absolute difference in fasting and non-fasting lipid profiles within individuals is lacking. Therefore, it is unknown whether current lipid treatment targets are suitable when using non-fasting lipid profiles.
Objective: To investigate whether a non-fasting lipid profile is as accurate and of equal clinical value as a fasting lipid profile for guiding lipid lowering therapy for secondary cardiovascular risk reduction.
Study design: Open randomized, cross-over trial where subjects are randomized between first measuring a fasting lipid profile followed by a non-fasting lipid profile on a separate day or vice versa.
Study population: Patients on lipid lowering therapy as secondary prevention for cardiovascular disease.
Main study endpoint: The number of re-classified patients that reach the treatment target of LDL-C <2.5 mmol/l when using non-fasting blood samples while their fasting LDL is >2.5mmol/l.
Risks, burden and benefits on participation: No major risks are involved besides a hematoma from the venipunctures or hypoglycemia due to fasting. Subjects need to visit the hospital two times, once fasting and, on another day, any time the subjects wish. During the two measurements it is not allowed to change lipid lowering therapy. Subjects receive an expense allowance of 10 euro’s upon participation. The potential benefit of the study is to demonstrate that a non-fasting lipid profile is accurate enough in comparison to a fasting lipid profile, which will ease the measurement of lipid levels for a large patient population worldwide.
Doel van het onderzoek
Current treatment targets for LDL-C, non-HDL-C and apo B can be used as accurately in the non-fasting state as in the fasting state. The measurement of LDL-C, non-HDL-C and apo B in the non-fasting state does not confer to an increased risk of falsely reaching the recommended treatment target.
Onderzoeksopzet
Not-applicable
Onderzoeksproduct en/of interventie
Open randomized, cross-over trial where subjects are randomized between first measuring a fasting lipid profile followed by a non-fasting lipid profile on a separate day or vice versa.
Algemeen / deelnemers
Boudewijn Klop
P.O. Box 444
Dordrecht 3300 AK
The Netherlands
Tel: 078-6550545
E-mail: b.klop@asz.nl
Wetenschappers
Boudewijn Klop
P.O. Box 444
Dordrecht 3300 AK
The Netherlands
Tel: 078-6550545
E-mail: b.klop@asz.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
Male and female patients, aged 18 years or older, from the outpatient department of Cardiology and Internal Medicine receiving lipid lowering therapy as secondary cardiovascular prevention are suitable for inclusion. Lipid lowering therapy is defined as the use of statins, fibrates, ezetimibe or nicotinic acid or a combination of these
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
A change in lipid lowering therapy within the last 4 weeks is an exclusion criterium for study participation.
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL4819 |
| NTR-old | NTR5321 |
| CCMO | NL51908.101.14 |
| OMON | NL-OMON41824 |
Samenvatting resultaten
3. Eberly, L. E., Stamler, J., and Neaton, J. D. (2003) Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease. Arch Intern Med.163, 1077-1083<br>
4. Mora, S., Rifai, N., Buring, J. E., and Ridker, P. M. (2008) Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. Circulation.118, 993-1001<br>
5. Nordestgaard, B. G., Benn, M., Schnohr, P., and Tybjaerg-Hansen, A. (2007) Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA.298, 299-308<br>
6. Langsted, A., and Nordestgaard, B. G. (2011) Nonfasting Lipids, Lipoproteins, and Apolipoproteins in Individuals with and without Diabetes: 58 434 Individuals from the Copenhagen General Population Study. Clin Chem.57, 482-489<br>
7. Klop, B., Cohn, J. S., van Oostrom, A. J., van Wijk, J. P., Birnie, E., and Castro Cabezas, M. (2011) Daytime triglyceride variability in men and women with different levels of triglyceridemia. Clin Chim Acta.412, 2183-2189<br>
8. Sidhu, D., and Naugler, C. (2012) Fasting time and lipid levels in a community-based population: a cross-sectional study. Arch Intern Med.172, 1707-1710<br>
9. de Vries, M., Klop, B., and Castro Cabezas, M. (2014) The use of the non-fasting lipid profile for lipid-lowering therapy in clinical practice - point of view. Atherosclerosis.234, 473-475<br>
10. Khera, A. V., and Mora, S. (2012) Fasting for lipid testing: is it worth the trouble?: comment on "fasting time and lipid levels in a community-based population". Arch Intern Med.172, 1710-1711